Fto-flox Mouse
Common Name
Fto-flox
제품 ID
S-CKO-09550
Backgroud
C57BL/6NCya
품종 계통계통 ID
CKOCMP-26383-Fto-B6N-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Fto-flox Mouse (카탈로그 번호 S-CKO-09550)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Fto-flox
품종 계통계통 ID
CKOCMP-26383-Fto-B6N-VA
유전자명
제품 ID
S-CKO-09550
유전자 별칭
mKIAA1752
배경
C57BL/6NCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 8
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000069718
NCBI 전사체 ID
NM_011936
타겟 영역
Exon 3
유효 영역 크기
~1.5 kb
유전자 연구 개요
Fto, short for fat mass and obesity associated protein, is the first reported RNA N6 -methyladenosine (m6A) demethylase in eukaryotic cells. m6A is a prevalent mRNA internal modification that impacts cellular processes such as alternative splicing, stability, and expression. Fto has been associated with various biological processes, including adipogenesis, nutrient sensing, regulation of mRNA translation, and general growth [1,2].
Genome-wide association studies (GWAS) have linked single-nucleotide polymorphisms (SNPs) within Fto to obesity, as well as multiple cancers like endometrial, breast, pancreatic, and melanoma [1]. In diabetes-induced vascular endothelial dysfunction, enhanced Fto reduces global m6A levels in hyperglycemia, and Fto knockdown in endothelial cells leads to less inflammation and compromised migration and tube formation abilities. EC-specific Fto-deficient (EC FtoΔ/Δ) diabetic mice show less retinal vascular leakage and acellular capillary formation, suggesting the Fto-TNIP1-NF-κB network could be a potential target for treating diabetic vascular complications [3]. In osteoporosis, variation in Fto disturbs m6A methylation in RNAs, regulating cell proliferation, differentiation, and apoptosis. Pharmacological inhibition of Fto affects bone mass, bone mineral density, and adipose tissue distribution, indicating Fto-targeting small molecules could be novel osteoporosis treatments [4]. In multiple myeloma, up-regulation of Fto leads to decreased m6A methylation in plasma cells, and Fto promotes tumor-promoting and pro-metastatic functions by post-transcriptionally activating HSF1 in an m6A-YTHDF2-dependent manner. Inhibition of Fto, especially combined with bortezomib, synergistically inhibits myeloma bone tumor formation and extramedullary spread [5].
In conclusion, Fto, as an m6A demethylase, plays crucial roles in multiple biological processes and diseases. Studies using gene knockout or conditional knockout mouse models, like the EC FtoΔ/Δ mice in diabetes-related vascular complications, have been instrumental in revealing Fto's functions. These findings in model-based research highlight Fto's significance in obesity, diabetes-related vascular diseases, osteoporosis, and multiple myeloma, providing potential therapeutic targets for these conditions.
References:
1. Azzam, Sarah Kassem, Alsafar, Habiba, Sajini, Abdulrahim A. 2022. FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms. In International journal of molecular sciences, 23, . doi:10.3390/ijms23073800. https://pubmed.ncbi.nlm.nih.gov/35409166/
2. Loos, Ruth J F, Yeo, Giles S H. 2013. The bigger picture of FTO: the first GWAS-identified obesity gene. In Nature reviews. Endocrinology, 10, 51-61. doi:10.1038/nrendo.2013.227. https://pubmed.ncbi.nlm.nih.gov/24247219/
3. Zhou, Chuandi, She, Xinping, Gu, Chufeng, Chen, Haibing, Zheng, Zhi. 2023. FTO fuels diabetes-induced vascular endothelial dysfunction associated with inflammation by erasing m6A methylation of TNIP1. In The Journal of clinical investigation, 133, . doi:10.1172/JCI160517. https://pubmed.ncbi.nlm.nih.gov/37781923/
4. Huang, Mei, Guo, Jianmin, Liu, Lifei, Chen, Xi, Zou, Jun. 2023. m6A demethylase FTO and osteoporosis: potential therapeutic interventions. In Frontiers in cell and developmental biology, 11, 1275475. doi:10.3389/fcell.2023.1275475. https://pubmed.ncbi.nlm.nih.gov/38020896/
5. Xu, Aoshuang, Zhang, Jiasi, Zuo, Liping, Sun, Chunyan, Hu, Yu. 2021. FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner. In Molecular therapy : the journal of the American Society of Gene Therapy, 30, 1104-1118. doi:10.1016/j.ymthe.2021.12.012. https://pubmed.ncbi.nlm.nih.gov/34915192/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
